Table 2. Adherence and persistence of metformin and sulfonylureas users prior to and following breast cancer diagnosis and treatment.

		Adherence					Persistence
		MPR			Adherent users (MPR ≥0.80)		Discontinuation episodes				DR	Persistent users (1–DR)
	N	Mean	SD	IQR	n	(%)	Mean	SD	Median	IQR	(%)	n	(%)
Year −1	509	0.86	0.26	0.67-0.99	383	75.3%	1.23	1.41	1	0-2	74.7%	129	25.3%
Treatment period	499	0.49*	0.31	0.25-0.67	123	24.6%*	1.06	1.25	1	0-1	59.3%	186	40.7%*
Year +1	438	0.48*	0.32	0.25-0.82	118	27.1%*	1.16	1.50	1	0-2	75.6%	107	24.4%
Year +2	413	0.48*	0.30	0.25-0.74	100	24.2%*	1.22	1.56	1	0-2	71.5%	118	28.5%
Year +3	385	0.52*	0.32	0.25-0.87	122	31.8%*	1.97	2.57	2	0-2	70.5%	113	29.5%

Abbreviations: MPR, medication possession ratio; DR, discontinuation rate; SD, standard deviation; IQR, interquartile range

Note: Statistical hypothesis tests were performed comparing means and proportions to baseline, Year −1 values;

^*indicates difference of statistical significance at P<0.001